Marc Cohen

Summary

Affiliation: Newark Beth Israel Medical Center
Country: USA

Publications

  1. doi request reprint Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion
    Marc Cohen
    Mount Sinai School of Medicine, New York, New York, USA
    J Interv Cardiol 21:283-99. 2008
  2. ncbi request reprint A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
    Marc Cohen
    HEART Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 48:1346-54. 2006
  3. doi request reprint Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial
    Marc Cohen
    Division of Cardiology, Cardiac Cath Lab, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Catheter Cardiovasc Interv 75:928-35. 2010
  4. doi request reprint Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 55:1895-906. 2010
  5. doi request reprint The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Am J Med 123:103-10. 2010
  6. pmc Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue at Osborne Terrace, Newark, NJ 07112, USA
    Cardiovasc Drugs Ther 23:489-99. 2009
  7. ncbi request reprint Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial
    Marc Cohen
    Cardiac Cath Lab Administration, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Circulation 108:III14-21. 2003
  8. doi request reprint Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, NJ, USA
    Catheter Cardiovasc Interv 74:579-97. 2009
  9. ncbi request reprint The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 42:1348-56. 2003
  10. pmc Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Mayo Clin Proc 84:149-60. 2009

Detail Information

Publications87

  1. doi request reprint Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion
    Marc Cohen
    Mount Sinai School of Medicine, New York, New York, USA
    J Interv Cardiol 21:283-99. 2008
    ..This article focuses on issues discussed during the roundtable from the perspective of the practicing cardiologist...
  2. ncbi request reprint A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes
    Marc Cohen
    HEART Hospital of New Jersey, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 48:1346-54. 2006
    ....
  3. doi request reprint Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial
    Marc Cohen
    Division of Cardiology, Cardiac Cath Lab, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Catheter Cardiovasc Interv 75:928-35. 2010
    ..To explore clinical and bleeding outcomes in patients enrolled in the SYNERGY trial who had percutaneous coronary intervention (PCI) based on adherence to the dosing regimens of enoxaparin mandated by the protocol...
  4. doi request reprint Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 55:1895-906. 2010
    ....
  5. doi request reprint The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical trials
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Am J Med 123:103-10. 2010
    ....
  6. pmc Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue at Osborne Terrace, Newark, NJ 07112, USA
    Cardiovasc Drugs Ther 23:489-99. 2009
    ..Non-ST-segment elevation acute coronary syndromes (NSTE ACS) are highly prevalent in the United States and globally, and are associated with significant morbidity and mortality...
  7. ncbi request reprint Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial
    Marc Cohen
    Cardiac Cath Lab Administration, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Circulation 108:III14-21. 2003
    ....
  8. doi request reprint Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, NJ, USA
    Catheter Cardiovasc Interv 74:579-97. 2009
    ....
  9. ncbi request reprint The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 42:1348-56. 2003
    ....
  10. pmc Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Mayo Clin Proc 84:149-60. 2009
    ..This comprehensive review contributes to the understanding of the benefit-to-risk ratio of antiplatelet therapy for patients with atherothrombosis...
  11. ncbi request reprint Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, PA, Philadelphia, USA
    Eur Heart J 24:1763-70. 2003
    ..To examine differences in patient characteristics and outcomes in 19636 patients enrolled in the USA and 3027 patients enrolled in other countries undergoing intra-aortic balloon pump (IABP) counterpulsation...
  12. doi request reprint Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?
    Marc Cohen
    Division of Cardiology, Cardiology Fellowship Training Program, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Curr Opin Cardiol 24:88-94. 2009
    ....
  13. doi request reprint The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Am J Emerg Med 26:932-41. 2008
    ..This review discusses each of these anticoagulant options in the context of patients transitioning to PCI...
  14. ncbi request reprint Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction
    Marc Cohen
    Division of Cardiology, Cardiac Catheterization Laboratory, Newark Beth Israel Center, Newark, NJ 07112, USA
    Am Heart Hosp J 3:82-7. 2005
    ..g., tenecteplase with enoxaparin), may be more efficacious and easier to use than regimens involving unfractionated heparin...
  15. ncbi request reprint Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them?
    Marc Cohen
    The Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, USA
    J Thromb Thrombolysis 26:175-82. 2008
    ..Investigators should justify components of bleeding endpoints as being clinically meaningful, sufficiently frequent in the study population, and affected by the intervention...
  16. ncbi request reprint Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
    Circulation 115:2642-51. 2007
    ..Otamixaban, a selective and direct inhibitor of factor Xa, was investigated in patients undergoing nonurgent percutaneous coronary intervention...
  17. ncbi request reprint Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III
    Marc Cohen
    Cardiac Cath Lab, 2nd Floor Bridge, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, 07112, USA
    J Invasive Cardiol 19:525-38; quiz 539-40. 2007
    ..The addition of statins, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease...
  18. doi request reprint Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Cardiovasc Electrophysiol 19:885-90. 2008
    ..Because of the limited efficacy and adverse effects of current antiarrhythmics, new antiarrhythmic drugs need to be developed that provide safer and more effective rhythm control in AF...
  19. doi request reprint High-risk acute coronary syndrome patients with non-ST-elevation myocardial infarction: definition and treatment
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA
    Cardiovasc Drugs Ther 22:407-18. 2008
    ..Early risk stratification of patients with acute coronary syndromes (ACS), unstable angina, or non-ST-elevation myocardial infarction ensures patients receive appropriate care...
  20. ncbi request reprint Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Center, Newark, NJ 07112, USA
    Curr Med Res Opin 21:439-45. 2005
    ....
  21. ncbi request reprint The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Cardiac Cath Lav Administration, New Jersey 07112, USA
    Am J Emerg Med 22:14-23. 2004
    ..More recent data can be interpreted as showing that regimens that are simpler and easier to administer are also clinically superior. This article reviews pharmacologic advances and evaluates the evidence for their use in EDs...
  22. ncbi request reprint The role of gender and other factors as predictors of not receiving reperfusion therapy and of outcome in ST-segment elevation myocardial infarction
    Marc Cohen
    Cardiac Catheterization Laboratory, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, 07112, USA
    J Thromb Thrombolysis 19:155-61. 2005
    ..We analyzed the impact of gender, and other factors, on the outcome and treatment of STEMI in the TETAMI trial and registry...
  23. ncbi request reprint Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry
    Gregg W Stone
    Cardiovascular Research Foundation and Lenox Hill Hospital, 55 East 59th Street, 6th Floor, New York, NY 10022, USA
    J Am Coll Cardiol 41:1940-5. 2003
    ..We sought to examine contemporary utilization patterns and clinical outcomes in patients with acute myocardial infarction (AMI) requiring intra-aortic balloon pump (IABP) counterpulsation...
  24. ncbi request reprint Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
    Marc Cohen
    MCP Hahnemann University School of Medicine, Philadelphia, PA, USA
    Am Heart J 144:470-7. 2002
    ..Replacing UFH with enoxaparin when tirofiban is administered to patients may offer further therapeutic benefit, but could also increase bleeding...
  25. ncbi request reprint Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease
    Heidar Arjomand
    Division of Cardiology, Department of Medicine, MCP Hahnemann University Hospitals, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
    J Invasive Cardiol 16:271-8. 2004
    ..0-2.5) in high-risk patients with atherosclerotic heart disease. Combination therapy increases the risk of minor and major bleeding, but not intracranial bleeding...
  26. doi request reprint A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial
    David A Baran
    Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Circ Heart Fail 4:129-37. 2011
    ..Retrospective reports suggested that single-drug immunosuppression with tacrolimus was feasible. As such, a prospective, randomized trial was conducted to test this approach...
  27. doi request reprint Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen
    Sargis Khoobiar
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, 07112, USA
    J Thromb Thrombolysis 26:85-90. 2008
    ..Enoxaparin use in PCI has been investigated, however its role in primary PCI is less known...
  28. ncbi request reprint Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial
    Gregg W Stone
    Cardiovascular Research Foundation, Lenox Hill Heart and Vascular Institute, New York, NY 10022, USA
    Circulation 105:2347-54. 2002
    ..Also unknown is whether the acuity of the presenting clinical syndrome, which may affect the degree of platelet inhibition required or achieved, influences the response to different antiplatelet agents...
  29. ncbi request reprint Defining optimal therapy for the thrombolysis-ineligible patient
    Marc Cohen
    Division of Cardiology, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA
    Clin Cardiol 25:I23-6. 2002
    ..Blinded data for the entire patient cohort shows excellent efficacy and safety in these patients...
  30. ncbi request reprint Comparison of outcomes after 8 vs. 9.5 French size intra-aortic balloon counterpulsation catheters based on 9,332 patients in the prospective Benchmark registry
    Marc Cohen
    Division of Cardiology, M C P Hahnemann University, Philadelphia, Pennsylvania, USA
    Catheter Cardiovasc Interv 56:200-6. 2002
    ..The large, population-based, ongoing Benchmark registry provides a useful vehicle for outcomes research concerning the evolving practice of IABC...
  31. doi request reprint The management of patients with atrial fibrillation and dronedarone's place in therapy
    Marc Cohen
    Cardiac Cath Laboratory, Newark Beth Israel Medical Center, NJ 07112, USA
    Adv Ther 28:1059-77. 2011
    ....
  32. doi request reprint Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY
    Sarah A Spinler
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA, USA
    Int J Cardiol 144:36-41. 2010
    ..We evaluated the effect of renal function on efficacy and outcomes in high-risk patients with NSTE ACS in the SYNERGY trial...
  33. doi request reprint Safety and efficacy of adjuvant glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction
    Zafar Iqbal
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA
    Am J Cardiol 111:1727-33. 2013
    ..The use of GPIs with TRA was associated with safer outcomes than using GPIs with a nontransradial approach. This study was limited in that it was a nonrandomized retrospective analysis...
  34. pmc Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions
    Zafar Iqbal
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Curr Cardiol Rev 8:181-91. 2012
    ....
  35. ncbi request reprint Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update
    Marc Cohen
    Division of Cardiology, MCP Hahnemann School of Medicine, Philadelphia, Pennsylvania 19102 1192, USA
    Drugs 62:1755-70. 2002
    ..New studies will investigate the use of these agents in patients with STEMI not undergoing thrombolysis and we await the results of these studies...
  36. ncbi request reprint Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, Philadelphia, Pennsylvania, USA
    Pharmacotherapy 22:542-6; author reply 546-50. 2002
  37. ncbi request reprint Unfractionated versus fractionated heparin for percutaneous coronary intervention
    Heidar Arjomand
    Cardiac Catheterization Laboratory, Mail Stop 119, Hahnemann University Hospital, Broad and Vine Streets, Philadelphia, PA 19102, USA
    Curr Cardiol Rep 4:327-33. 2002
    ..This article reviews the current status of anticoagulation therapy with unfractionated heparin and LMWHs in the cardiac catheterization laboratory...
  38. ncbi request reprint Platelets and antiplatelet therapy in patients with diabetes mellitus
    Heidar Arjomand
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA
    J Invasive Cardiol 15:264-9. 2003
    ..Treatment with glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention reduces mortality in diabetic patients...
  39. ncbi request reprint Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, Philadelphia, Pennsylvania, USA
    Am Heart J 143:63-9. 2002
    ..To examine the mode and timing of subsequent cardiac events, we analyzed pooled data from the ESSENCE and TIMI 11B studies of antithrombotic therapy in NSTEMI ACS...
  40. doi request reprint Pitfalls associated with the use of current recommendations for fluoroscopy-guided common femoral artery access
    Vamsee Yaganti
    Division of Cardiology, Newark Beth Israel Medical Centre, Newark, New Jersey 07112, USA
    Catheter Cardiovasc Interv 81:674-9. 2013
    ..However, the use of current recommendations still results in arterial access above the inferior epigastric artery (IEA) (high stick) or below the common femoral artery (CFA) bifurcation (low stick)...
  41. doi request reprint Feasibility of the 3D RCA catheter to engage the brachiocephalic vessels during carotid angiography and stenting
    Najam Wasty
    Division of Cardiology, Department of Medicine, Newark Beth Israel Medical Center, Newark, New Jersey, USA
    Catheter Cardiovasc Interv 77:742-5. 2011
    ..In this study, we evaluated the feasibility of using the 3D RCA catheter which requires less manipulation in the aorta, and less training, to engage the brachiocephalic vessels...
  42. ncbi request reprint The role of low-molecular-weight heparin in the management of acute coronary syndromes
    Marc Cohen
    Newark Beth Israel Medical Center, Division of Cardiology, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 41:55S-61S. 2003
    ....
  43. doi request reprint Improving long-term ACS management: is there a role for the new antiplatelets?
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Interv Cardiol 25:425-32. 2012
    ....
  44. doi request reprint Enoxaparin: a pharmacologic and clinical review
    Zafar Iqbal
    Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Expert Opin Pharmacother 12:1157-70. 2011
    ..As anticoagulants play a pivotal role in the treatment of these disorders, it is vital for healthcare providers to have sufficient knowledge of their biochemical and clinical attributes...
  45. doi request reprint ED to catheterization laboratory: a roundtable integrating trials with practice
    Charles V Pollack
    University of Pennsylvania School of Medicine, PA, USA
    Am J Emerg Med 29:1203-16. 2011
    ..As a result, other factors (eg, individual patient characteristics, clinician experience, cost, regulatory labels, expert opinions) often result in clinical decision-making that varies from strict adherence to guideline recommendations...
  46. doi request reprint US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA
    J Thromb Thrombolysis 33:230-8. 2012
    ....
  47. ncbi request reprint The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures
    Soumaya El Rouby
    Clinical Affairs and Research and Development, ITC, Edison, NJ, USA
    J Thromb Thrombolysis 21:137-45. 2006
    ..The objective of this study was to evaluate a new point-of-care test (POCT) HEMONOX in monitoring the anticoagulant effect of enoxaparin in non citrated fresh whole blood samples from patients undergoing elective PCI procedure...
  48. ncbi request reprint Impact of intra-aortic balloon counterpulsation with different balloon volumes on cardiac performance in humans
    Marc Cohen
    Division of Cardiology, MCP Hahnemann University School of Medicine, Philadelphia, Pennsylvania, USA
    Catheter Cardiovasc Interv 57:199-204. 2002
    ..40 cc (P = 0.05). Overall, smaller IAB inflation volumes do not affect the hemodynamic improvement seen during IAB counterpulsation. However, in patients with smaller BSA, larger inflation volumes may further augment CO...
  49. doi request reprint Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial
    Manesh R Patel
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    JAMA 306:1329-37. 2011
    ..Intra-aortic balloon counterpulsation (IABC) is an adjunct to revascularization in patients with cardiogenic shock and reduces infarct size when placed prior to reperfusion in animal models...
  50. doi request reprint Emerging antithrombotic agents: what does the intensivist need to know?
    Zafar Iqbal
    Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ 07112, USA
    Curr Opin Crit Care 16:419-25. 2010
    ..As thrombus consists of both fibrin and platelets, antithrombotic strategies involve anticoagulants and antiplatelets, alone or in combination...
  51. doi request reprint Staphylococcus capitis prosthetic valve endocarditis: report of two rare cases and review of literature
    Sandhya Nalmas
    Division of Infectious Diseases, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    Heart Lung 37:380-4. 2008
    ..We report two cases of S.capitis prosthetic valve endocarditis, both involving prosthetic aortic valve and complicated by aortic root abscess. We also review the literature for this rare condition caused by this rare organism...
  52. doi request reprint Interatrial thrombus-in-transit resulting in paradoxical thromboembolism
    Sargis Khoobiar
    Newark Beth Israel Medical Center, Newark, NJ, USA
    J Thromb Thrombolysis 29:127-9. 2010
    ....
  53. ncbi request reprint Association of carotid artery intima-media thickness with complex aortic atherosclerosis in patients with recent stroke
    Panayotis Fasseas
    Division of Cardiology, MCP Hahnemann University, Philadelphia, PA 19102, USA
    Angiology 53:185-9. 2002
    ..Carotid intimamedia thickness measurement can be used to noninvasively estimate the probability of complex aortic atherosclerosis. A carotid intima-media thickness less than 2 mm makes complex aortic atherosclerosis very unlikely...
  54. ncbi request reprint Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone compared (the TICTAC trial)
    David A Baran
    Department of Medicine, Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Heart Lung Transplant 26:992-7. 2007
    ..Prior retrospective studies have suggested that tacrolimus monotherapy is an option associated with excellent outcomes and reduced toxicities...
  55. ncbi request reprint Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus
    Dean J Kereiakes
    Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 144:615-24. 2002
    ....
  56. ncbi request reprint Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study
    James J Ferguson
    Cardiology Research 1 191, St Luke s Episcopal Hospital, Houston, Tex 77225, USA
    Am Heart J 146:628-34. 2003
    ....
  57. ncbi request reprint Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19104, USA
    Am Heart J 146:33-41. 2003
    ..However, no data are available about the safety and efficacy in patients who are obese and patients with severe renal impairment...
  58. ncbi request reprint Identification of patients at high risk for death and cardiac ischemic events after hospital discharge
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:966-70. 2002
    ..Patients with unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) remain at risk for death and cardiac ischemic events after being discharged from the hospital...
  59. ncbi request reprint Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia
    Bruce E Lewis
    Loyola University Medical Center, Maywood, Illinois, USA
    Catheter Cardiovasc Interv 57:177-84. 2002
    ..Overall, outcomes were comparable with those historically reported for heparin. Argatroban therefore is a reasonable anticoagulant option in this setting, where current options are limited...
  60. ncbi request reprint Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention
    Keith A A Fox
    Edinburgh Royal Infirmary, Edinburgh, United Kingdom
    Am J Cardiol 90:477-82. 2002
    ..Nevertheless, in the absence of large clinical trials, this study suggests that treatment with enoxaparin was well tolerated, and exhibited a similar risk of major hemorrhage to UFH in patients who underwent PCI...
  61. ncbi request reprint Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:20-5. 2003
    ..This study was designed to assess whether use of enoxaparin during percutaneous coronary intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to background therapy with eptifibatide...
  62. ncbi request reprint Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation
    Marc Cohen
    Thromb Haemost 88:884-6; 886-7. 2002
  63. doi request reprint Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:43-81. 2008
    ..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS...
  64. ncbi request reprint Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave C
    Nick R Bijsterveld
    Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
    J Am Coll Cardiol 42:2083-9. 2003
    ....
  65. ncbi request reprint Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:2238-46. 2007
    ....
  66. ncbi request reprint Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Catheter Cardiovasc Interv 69:73-83. 2007
    ..Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS)...
  67. ncbi request reprint Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 152:1042-50. 2006
    ..The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding...
  68. ncbi request reprint Strategies for optimizing outcomes in the NSTE-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report
    Marc Cohen
    J Invasive Cardiol 18:617-39. 2006
    ..The addition of statins, ACE-inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease...
  69. ncbi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...
  70. ncbi request reprint Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2077-86. 2007
    ....
  71. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  72. ncbi request reprint Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin
    Silvio Zalc
    Heart Institute InCor, University of Sao Paulo Medical School, Brazil
    J Invasive Cardiol 18:45-8. 2006
    ..The primary objective of this study was to assess the feasibility of immediate sheath removal post-PCI in patients given a single low-dose intravenous (IV) bolus of enoxaparin as the sole anticoagulant...
  73. ncbi request reprint Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
    John L Petersen
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:269-76. 2004
    ..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
  74. ncbi request reprint In-hospital mortality associated with the use of intra-aortic balloon counterpulsation
    Philip M Urban
    La Tour Hospital, Geneva, Switzerland
    Am J Cardiol 94:181-5. 2004
    ..Therefore, diagnostic evaluation and treatment decisions should be made as early as possible, and physicians should be aware of associated risk factors in making choices for patients...
  75. ncbi request reprint The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy
    Shaun G Goodman
    Division of Cardiology, Canadian Heart Research Centre, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Am Heart J 151:791-7. 2006
    ....
  76. pmc Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Gen Intern Med 23:310-6. 2008
    ..Despite advances in pharmacologic therapy and invasive management strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), these patients still suffer substantial morbidity and mortality...
  77. doi request reprint Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
    Gilles Montalescot
    Institut de Cardiologie AP HP and INSERM Unit no 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 29:462-71. 2008
    ..To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding...
  78. doi request reprint Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
    Steve Leung
    University of Kentucky, Lexington, KY, USA
    Am Heart J 156:177-84. 2008
    ..Smoking remains a major public health issue. We investigated the incidence of smoking and outcomes in high-risk patients with acute coronary syndromes. Differences in treatment effect of antithrombin therapies were also investigated...
  79. ncbi request reprint Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial
    James J Ferguson
    JAMA 292:45-54. 2004
    ..Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy...
  80. ncbi request reprint High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2594-600. 2005
    ....
  81. ncbi request reprint Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA
    Curr Med Res Opin 22:1109-22. 2006
    ..This, however, creates a clinical dilemma, since discontinuing VKAs may place the patient at risk of thromboembolism...
  82. ncbi request reprint Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial
    Jerrold H Levy
    Emory University Hospital, Atlanta, GA, USA
    J Thorac Cardiovasc Surg 124:35-42. 2002
    ..This study examined the hypothesis that a hemoglobin-based oxygen-carrying solution can serve as an initial alternative to red blood cell transfusion...
  83. pmc C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression
    Ramona S Scotland
    Wolfson Institute for Biomedical Research, University College London, Cruciform Building, Gower Street, London WC1E 6AE, United Kingdom
    Proc Natl Acad Sci U S A 102:14452-7. 2005
    ..These observations suggest that endothelial CNP might maintain an anti-atherogenic influence on the blood vessel wall and represent a target for therapeutic intervention in inflammatory cardiovascular disorders...
  84. ncbi request reprint Progress with diabetic patients undergoing percutaneous coronary intervention
    Marc Cohen
    Eur Heart J 25:99-100. 2004
  85. ncbi request reprint Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery
    Jan T Christenson
    Department of Cardiovascular Surgery, University Hospital, Geneva, Switzerland
    Ann Thorac Surg 74:1086-90; discussion 1090-1. 2002
    ..Although the efficacy and cost-effectiveness of IABC have been demonstrated, historically higher complication rates have dissuaded some practitioners from using IABC...
  86. ncbi request reprint A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee
    Marc Cohen
    Department of Complementary Medicine, Faculty of Life Sciences, RMIT University, Bundoora, Australia
    J Rheumatol 30:523-8. 2003
    ..To assess the ability of a topical preparation of glucosamine sulfate and chondroitin sulfate to reduce pain related to osteoarthritis (OA) of the knee...
  87. ncbi request reprint Preoperative IABP in high-risk patients reduces postoperative lactate release and subsequent mortality
    Jan T Christenson
    Ann Thorac Surg 73:1026-7. 2002